A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer

被引：0
|
作者：
Otto Metzger Filho
Anita Giobbie-Hurder
Nancy U. Lin
Meredith Faggen
Steven Come
Thomas Openshaw
Michael Constantine
Jeanna Walsh
Rachel A. Freedman
Bryan Schneider
Harold J. Burstein
Erica L. Mayer
机构：
[1] Dana-Farber Cancer Institute,Susan F. Smith Center for Women’s Cancers
[2] Beth Israel Deaconess Medical Center,undefined
[3] Eastern Maine Medical Center,undefined
[4] Simon Cancer Center at Indiana University,undefined
[5] Dana-Farber Cancer Institute,undefined
来源：
Breast Cancer Research and Treatment | 2021年 / 185卷
关键词：
Breast cancer; Eribulin; Adverse event; CTCAE; PRO-CTCAE;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：135 / 144
页数：9
相关论文
共 50 条
  • [1] A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
    Metzger Filho, Otto
    Giobbie-Hurder, Anita
    Lin, Nancy U.
    Faggen, Meredith
    Come, Steven
    Openshaw, Thomas
    Constantine, Michael
    Walsh, Jeanna
    Freedman, Rachel A.
    Schneider, Bryan
    Burstein, Harold J.
    Mayer, Erica L.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 135 - 144
  • [2] A retrospective comparison of eribulin and capecitabine in patients with HER2-negative metastatic breast cancer
    Tsushita, N.
    Shimoi, T.
    Okuma, H. S.
    Kawachi, A.
    Kitano, A.
    Nishikawa, T.
    Shimomura, A.
    Noguchi, E.
    Kodaira, M.
    Yunokawa, M.
    Yonemori, K.
    Shimizu, C.
    Fujiwara, Y.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
    Landry, Chrystal A.
    Blanter, Julia
    Ru, Meng
    Fasano, Julie
    Klein, Paula
    Shao, Theresa
    Bhardwaj, Aarti
    Tiersten, Amy
    ONCOLOGY, 2023,
  • [4] Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
    Landry, Chrystal A.
    Blanter, Julia
    Ru, Meng
    Fasano, Julie
    Klein, Paula
    Shao, Theresa
    Bhardwaj, Aarti
    Tiersten, Amy
    ONCOLOGY, 2023,
  • [5] Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
    Landry, Chrystal A.
    Blanter, Julia
    Ru, Meng
    Fasano, Julie
    Klein, Paula
    Shao, Theresa
    Bhardwaj, Aarti
    Tiersten, Amy
    ONCOLOGY, 2024, 102 (01) : 9 - 16
  • [6] Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.
    Chen, Nan
    Michaels, Elena
    Saha, Poornima
    Rampurwala, Murtuza M.
    Hahn, Olwen Mary
    Howard, Frederick Matthew
    Fleming, Gini F.
    Karrison, Theodore
    Conzen, Suzanne D.
    Nanda, Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
    Takashima, Tsutomu
    Tokunaga, Shinya
    Tei, Seika
    Nishimura, Shigehiko
    Kawajiri, Hidemi
    Kashiwagi, Shinichiro
    Yamagata, Shigehito
    Noda, Satoru
    Nishimori, Takeo
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Onoda, Naoyoshi
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    SPRINGERPLUS, 2016, 5 : 1 - 8
  • [8] Results of a phase Ib study investigating durvalumab in combination with eribulin in patients with metastatic HER2-negative breast cancer and recurrent ovarian cancer.
    Landry, Chrystal Ann
    Ru, Meng
    Hickson, Christopher
    Klein, Paula
    Fasano, Julie
    Bhardwaj, Aarti
    Shapiro, Charles L.
    Irie, Hanna
    Shao, Theresa
    Selkridge, Isaiah
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Combination treatment for HER2-negative, advanced breast cancer
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (04) : 315 - 315
  • [10] Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study
    Yin, Y.
    Wu, X.
    Huang, X.
    Li, W.
    Hua, Y.
    Liang, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S648 - S649
12345